New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 8 #8/9/10 February 2006


MEETING COVERAGE

NOVEL ANTICANCER AGENTS/FORMULATIONS IN PHASE I MONOTHERAPY CLINICAL TRIALS
FROM THE 2005 MEETINGS OF THE AMERICAN ASSOCIATION OF CANCER RESEARCH, THE NATIONAL CANCER INSTITUTE, AND THE EUROPEAN SOCIETY FOR THE RESEARCH AND TREATMENT OF CANCER (AACR-NCI-EORTC), AND THE AMERICAN SOCIETY OF HEMATOLOGY (ASH)

CYTOTOXIC AGENTS/TARGETED CYTOTOXICS/CELL-CYCLE MODULATORS/APOPTOSIS INDUCERS/IMMUNOCONJUGATES
  • Cell-cycle Modulators
    • AG-024322
    • AT7519
    • R04584820
  • Spindle Poisons
    • BI 2536
    • C242-DM4
    • TPI-287
    • TTI-237
  • Other Cytotoxics/Apoptosis Inducers
    • Azaspirane
    • CB3304
    • ES-285
    • PM00104
    • PT-523
    • RH1
    • RTA 401(CDDO) and RTA 402 (CDDO-Me)
    • RTA 744 (WP774) and RTA 769
    • S23906
    • S-CKD602
    • SJG-136
    • ZIO-101

TARGETED AGENTS (REGULATORY AGENTS)/CYTOSTATICS/ANGIOGENESIS INHIBITORS

  • Angiogenesis Inhibitors
    • BIBF 1120
    • CHIR258 (CHIR258LC)
    • CP-868,596
    • ENMD-1198
    • OSI-930
    • XL880
  • Aurora Kinase Inhibitors
    • AZD1152
    • MK0457 (VX-680)
    • MLN8054
  • Epidermal Growth Factor Receptor (EGFr) Inhibitors
    • ARRY-33454
    • BIBW 2992
    • XL647
  • Heat-shock Protein 90 (Hsp90) Inhibitors
    • CNF-1010
    • IPI-504
    • KOS-1022
  • Other Targeted Therapeutics
    • AGS-PSCA
    • AZD6244 (ARRY-142886)
    • GX15-070
    • PD0325901
    • PRO1762
    • SPC2996

IMMUNOTHERAPEUTICS/VACCINES

  • CHIR-12.12
  • SGN-40
  • TACI-Ig


LIST OF EXHIBITS

Exhibit 1 - Anticancer Agents in Phase I Monotherapy Clinical Trials with Recently Reported Preclinical or Clinical Findings

Exhibit 2 - Molecular Targets of Anticancer Agents in Phase I Monotherapy Clinical Trials


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887